ECSP11011246A - Métodos para reducir la proliferación y viabilidad de los agentes microbianos - Google Patents
Métodos para reducir la proliferación y viabilidad de los agentes microbianosInfo
- Publication number
- ECSP11011246A ECSP11011246A EC2011011246A ECSP11011246A ECSP11011246A EC SP11011246 A ECSP11011246 A EC SP11011246A EC 2011011246 A EC2011011246 A EC 2011011246A EC SP11011246 A ECSP11011246 A EC SP11011246A EC SP11011246 A ECSP11011246 A EC SP11011246A
- Authority
- EC
- Ecuador
- Prior art keywords
- viability
- proliferation
- reduce
- methods
- microbial agents
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/65—Tetracyclines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
La invención se relaciona con formulaciones de un agente antimicrobiano, un lípido y, opcionalmente, un surfactante, y los usos de las mismas para reducir la proliferación y viabilidad de los agentes microbianos.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15028809P | 2009-02-05 | 2009-02-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP11011246A true ECSP11011246A (es) | 2011-11-30 |
Family
ID=41460484
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EC2011011246A ECSP11011246A (es) | 2009-02-05 | 2011-08-04 | Métodos para reducir la proliferación y viabilidad de los agentes microbianos |
Country Status (19)
Country | Link |
---|---|
US (2) | US20100197621A1 (es) |
EP (1) | EP2393480A1 (es) |
JP (1) | JP2012516889A (es) |
KR (1) | KR20110128283A (es) |
CN (1) | CN102368998A (es) |
AU (1) | AU2009339445A1 (es) |
BR (1) | BRPI0924302A2 (es) |
CA (1) | CA2751412A1 (es) |
CO (1) | CO6410285A2 (es) |
CR (1) | CR20110409A (es) |
EC (1) | ECSP11011246A (es) |
IL (1) | IL214331A0 (es) |
MX (1) | MX2011008204A (es) |
NI (1) | NI201100152A (es) |
PE (1) | PE20120326A1 (es) |
RU (1) | RU2011136624A (es) |
SG (1) | SG173183A1 (es) |
WO (1) | WO2010090654A1 (es) |
ZA (1) | ZA201105758B (es) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090175810A1 (en) | 2008-01-03 | 2009-07-09 | Gareth Winckle | Compositions and methods for treating diseases of the nail |
US20120232034A1 (en) | 2009-08-21 | 2012-09-13 | Henk-Andre Kroon | Vesicular formulations |
MX337804B (es) | 2010-05-19 | 2016-03-18 | Sandoz Ag | Proceso para la preparacion de hidrazinas quirales. |
EP2571871B1 (en) | 2010-05-19 | 2017-06-21 | Sandoz AG | Process for the preparation of chiral triazolones |
CA2798007C (en) | 2010-05-19 | 2018-10-23 | Sandoz Ag | Preparation of posaconazole intermediates |
JP5955837B2 (ja) | 2010-05-19 | 2016-07-20 | サンド・アクチエンゲゼルシヤフト | ポサコナゾール及びポサコナゾール中間体の精製 |
US8039494B1 (en) | 2010-07-08 | 2011-10-18 | Dow Pharmaceutical Sciences, Inc. | Compositions and methods for treating diseases of the nail |
BR112013015085A8 (pt) * | 2010-12-16 | 2018-04-03 | Univ Texas | Composição farmacêutica, método para preparar uma composição, e, uso de composição |
AU2012229068B2 (en) * | 2011-03-15 | 2015-09-03 | Thompson Cooper Laboratories, Llc | Compositions and methods for treatment of infections |
WO2012126966A2 (en) * | 2011-03-21 | 2012-09-27 | Gregor Cevc | Optimised preparations of highly adaptable aggregates |
AU2012250050B2 (en) | 2011-04-28 | 2017-04-06 | Platform Brightworks Two, Ltd. | Improved parenteral formulations of lipophilic pharmaceutical agents and methods for preparing and using the same |
CA2838051C (en) | 2011-06-16 | 2019-09-24 | Sandoz Ag | Process for the preparation of a chiral compound |
WO2013043830A1 (en) * | 2011-09-20 | 2013-03-28 | Molecular Express, Inc. | Nanoparticle formulations of poorly soluble compounds |
KR101350442B1 (ko) * | 2011-10-12 | 2014-01-15 | 김동진 | 클로르헥시딘을 함유하는 안정한 수용성 살균방부제 조성물 |
WO2013057208A1 (en) | 2011-10-18 | 2013-04-25 | Targeted Delivery Technologies Limited | Compositions and methods for reducing the proliferation and viability of microbial agents |
GB201205642D0 (en) | 2012-03-29 | 2012-05-16 | Sequessome Technology Holdings Ltd | Vesicular formulations |
CN102659734B (zh) * | 2012-04-28 | 2014-07-16 | 山东大学 | 一种三烯抗生素的制备方法 |
CN104379132A (zh) * | 2012-06-14 | 2015-02-25 | 桑多斯股份公司 | 包含结晶泊沙康唑的药物组合物 |
WO2014062621A1 (en) | 2012-10-15 | 2014-04-24 | Stc.Unm | Treatment of autophagy-based disorders and related pharmaceutical compositions, diagnostic and screening assays and kits |
US8815952B1 (en) * | 2013-03-15 | 2014-08-26 | Carnell & Herzog, LLC | Chlorhexadine antiseptic |
JP6206907B2 (ja) * | 2013-07-16 | 2017-10-04 | 株式会社ゲノム創薬研究所 | 抗菌活性促進剤及び該抗菌活性促進剤を含有する感染症治療薬 |
US9662394B2 (en) * | 2013-10-03 | 2017-05-30 | Dow Pharmaceutical Sciences, Inc. | Stabilized efinaconazole compositions |
CA2931144C (en) | 2013-11-22 | 2020-02-04 | Dow Pharmaceutical Sciences, Inc. | Anti-infective methods, compositions, and devices |
CN103690543B (zh) * | 2013-12-24 | 2015-09-09 | 广西医科大学 | 杀死烟曲霉菌的组合物及方法 |
ES2879383T3 (es) | 2015-06-30 | 2021-11-22 | Sequessome Tech Holdings Limited | Fórmulas mixtas |
CN106546668A (zh) * | 2015-09-22 | 2017-03-29 | 陕西合成药业股份有限公司 | 一种分离福司氟康唑或其药用盐有关物质的hplc方法 |
CN106890167A (zh) * | 2015-12-17 | 2017-06-27 | 中国科学院上海巴斯德研究所 | 一种具有抗结核活性的化合物及其应用 |
AU2016377340B2 (en) * | 2015-12-22 | 2019-10-31 | 3M Innovative Properties Company | Methods for spore removal |
WO2017188692A1 (ko) * | 2016-04-25 | 2017-11-02 | 경북대학교 산학협력단 | 7,10-에폭시옥타데카-7,9-다이에노산을 유효성분으로 포함하는 항균 조성물 |
KR101792239B1 (ko) | 2016-11-01 | 2017-10-31 | 경북대학교 산학협력단 | 7,10-에폭시옥타데카-7,9-다이에노산 및 항생제를 유효성분으로 포함하는 항균 조성물 |
KR101749687B1 (ko) | 2016-04-25 | 2017-06-21 | 경북대학교 산학협력단 | 7,10-에폭시옥타데카-7,9-다이에노산을 유효성분으로 포함하는 항균 조성물 |
CN107184551B (zh) * | 2017-06-09 | 2020-09-01 | 甘肃新天马制药股份有限公司 | 一种利拉萘酯双粒径分布乳剂及其制备方法 |
CN112791048B (zh) * | 2020-12-31 | 2023-01-17 | 海南海神同洲制药有限公司 | 一种硝酸舍他康唑栓及其制备方法 |
CN112931213B (zh) * | 2021-03-29 | 2022-05-27 | 东北林业大学 | 一种杨树外植体脱毒试剂、脱毒方法及应用 |
CN114432297B (zh) * | 2022-02-07 | 2022-10-11 | 中国人民解放军军事科学院军事医学研究院 | Zaragozic acid A在产气荚膜梭菌Epsilon毒素中毒救治中的应用 |
CN115644062B (zh) * | 2022-11-03 | 2023-11-17 | 天津科润农业科技股份有限公司 | 一种提高难出胚大白菜胚诱导率的培养基及其方法 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6348214A (ja) * | 1986-08-18 | 1988-02-29 | Morishita Seiyaku Kk | 1−〔2−(2,4−ジクロロフエニル)−3−メチル−1−ペンテニル〕−1h−イミダゾ−ルを含有する水中油型脂肪乳剤 |
US6165500A (en) * | 1990-08-24 | 2000-12-26 | Idea Ag | Preparation for the application of agents in mini-droplets |
GB9111611D0 (en) * | 1991-05-30 | 1991-07-24 | Sandoz Ltd | Liposomes |
US5536729A (en) * | 1993-09-30 | 1996-07-16 | American Home Products Corporation | Rapamycin formulations for oral administration |
DE4336434A1 (de) * | 1993-10-26 | 1995-04-27 | Hoechst Ag | Pharmazeutische Zubereitung für die parenterale, enterale und dermale Verabreichung von praktisch unlöslichen Arzneistoffen und Verfahren zu ihrer Herstellung |
AU3257397A (en) * | 1996-06-07 | 1998-01-07 | Gist-Brocades B.V. | Antifungal compositions |
EP0872229A1 (en) * | 1997-04-14 | 1998-10-21 | Janssen Pharmaceutica N.V. | Compositions containing an antifungal and a phospholipid |
DK1079808T3 (da) * | 1998-05-29 | 2004-06-07 | Skyepharma Canada Inc | Præparater med termisk beskyttede mikropartikler og fremgangsmåde til slutdampsterilisering deraf |
US20030215493A1 (en) * | 2002-04-30 | 2003-11-20 | Patel Pravin M. | Composition and method for dermatological treatment |
US6846837B2 (en) * | 2002-06-21 | 2005-01-25 | Howard I. Maibach | Topical administration of basic antifungal compositions to treat fungal infections of the nails |
US20040105881A1 (en) * | 2002-10-11 | 2004-06-03 | Gregor Cevc | Aggregates with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin |
CA2579805A1 (en) * | 2004-09-03 | 2006-03-16 | Piedmont Pharmaceuticals, Llc | Methods for transmembrane treatment and prevention of otitis media |
US8633191B2 (en) * | 2004-09-21 | 2014-01-21 | Stephen C. Perry | Anti-microbial and anti-fungal shampoo for mammals especially humans and dogs |
US20060078580A1 (en) * | 2004-10-08 | 2006-04-13 | Mediquest Therapeutics, Inc. | Organo-gel formulations for therapeutic applications |
US20060222716A1 (en) * | 2005-04-01 | 2006-10-05 | Joseph Schwarz | Colloidal solid lipid vehicle for pharmaceutical use |
CN101273971A (zh) * | 2008-05-09 | 2008-10-01 | 绍兴文理学院 | 抗真菌药物的醇质体制剂及其制备方法 |
KR20110039357A (ko) * | 2008-07-23 | 2011-04-15 | 타겟티드 딜리버리 테크놀러지스 리미티드 | 진균 감염 치료를 위해 국부 항진균 제제를 투여하는 방법 |
-
2009
- 2009-07-23 US US12/508,494 patent/US20100197621A1/en not_active Abandoned
- 2009-07-23 EP EP09744247A patent/EP2393480A1/en not_active Withdrawn
- 2009-07-23 BR BRPI0924302A patent/BRPI0924302A2/pt not_active IP Right Cessation
- 2009-07-23 WO PCT/US2009/051593 patent/WO2010090654A1/en active Application Filing
- 2009-07-23 SG SG2011054749A patent/SG173183A1/en unknown
- 2009-07-23 JP JP2011549138A patent/JP2012516889A/ja not_active Withdrawn
- 2009-07-23 MX MX2011008204A patent/MX2011008204A/es not_active Application Discontinuation
- 2009-07-23 PE PE2011001447A patent/PE20120326A1/es not_active Application Discontinuation
- 2009-07-23 CA CA2751412A patent/CA2751412A1/en not_active Abandoned
- 2009-07-23 CN CN2009801584799A patent/CN102368998A/zh active Pending
- 2009-07-23 AU AU2009339445A patent/AU2009339445A1/en not_active Abandoned
- 2009-07-23 KR KR1020117020470A patent/KR20110128283A/ko not_active Application Discontinuation
- 2009-07-23 RU RU2011136624/15A patent/RU2011136624A/ru unknown
-
2011
- 2011-07-28 CR CR20110409A patent/CR20110409A/es unknown
- 2011-07-28 IL IL214331A patent/IL214331A0/en unknown
- 2011-08-04 EC EC2011011246A patent/ECSP11011246A/es unknown
- 2011-08-04 NI NI201100152A patent/NI201100152A/es unknown
- 2011-08-04 ZA ZA2011/05758A patent/ZA201105758B/en unknown
- 2011-08-05 CO CO11099579A patent/CO6410285A2/es not_active Application Discontinuation
-
2012
- 2012-06-07 US US13/491,474 patent/US20120245107A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
KR20110128283A (ko) | 2011-11-29 |
MX2011008204A (es) | 2011-12-06 |
SG173183A1 (en) | 2011-09-29 |
ZA201105758B (en) | 2013-01-30 |
CA2751412A1 (en) | 2010-08-12 |
US20120245107A1 (en) | 2012-09-27 |
US20100197621A1 (en) | 2010-08-05 |
NI201100152A (es) | 2012-03-28 |
WO2010090654A1 (en) | 2010-08-12 |
BRPI0924302A2 (pt) | 2019-09-24 |
CN102368998A (zh) | 2012-03-07 |
IL214331A0 (en) | 2011-09-27 |
AU2009339445A1 (en) | 2011-08-18 |
JP2012516889A (ja) | 2012-07-26 |
CO6410285A2 (es) | 2012-03-30 |
CR20110409A (es) | 2011-11-02 |
EP2393480A1 (en) | 2011-12-14 |
PE20120326A1 (es) | 2012-04-20 |
RU2011136624A (ru) | 2013-03-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP11011246A (es) | Métodos para reducir la proliferación y viabilidad de los agentes microbianos | |
AR081681A1 (es) | METODOS Y COMPOSICIONES PARA LA ADMINISTRACION INTRATECAL DE b-GALACTOCEREBROSIDASA | |
ECSP13012877A (es) | FORMAS SÓLIDAS SDE 3- (5-AMINO-2-metil -4- oxo-4H-QUINAZOL1N-3-IL) - PIPERIDIN-2, 6-DIONA, Y SUS COMPOSICIONES FARMACÉUTICAS Y USOS | |
UY35351A (es) | Formulaciones acuosas estables de adalimumab | |
CL2014001291A1 (es) | Agentes de iarn de doble hebra; composiciones y metodos de uso de los mismos para tratar enfermedades asociadas con transtiretina (ttr). | |
UA112086C2 (uk) | Гербіцидні композиції, що включають хлорацетаміди | |
BR112013021509A2 (pt) | composições para cuidado pessoal | |
BR112013013402A2 (pt) | combinações de ingredientes ativos que compreendem piridiletilbenzamidas e outros ingredientes ativos | |
NZ631152A (en) | Eutectic formulations of cyclobenzaprine hydrochloride and amitriptyline hydrochloride | |
ECSP11010818A (es) | Métodos para administrar formulaciones antifúngicas tópicas para el tratamiento de infecciones fúngicas | |
ECSP10010548A (es) | Composiciones y metodos de preparacion y uso de las mismas | |
CL2014003225A1 (es) | Composición que comprende un agente de control biológico y un fungicida. | |
ECSP11011487A (es) | Pirazinilpirazoles | |
UY34413A (es) | Formulaciones, composiciones, metabolitos de chro mobacterium y sus usos | |
CR20150310A (es) | Solución para preservar conductos vasculares | |
CR20140505A (es) | (r) -nifuratel y sintesis de (r) - nifuratel | |
PH12014502858A1 (en) | Racecadotril lipid compositions | |
SMT201500235B (it) | Formulazione comprendente derivato di fenilamminopirimidina come agente attivo | |
CO6761388A2 (es) | Composiciones pharmaceuticas que comprenden alisporivir | |
MY162688A (en) | Oral care compositions | |
GT201300225A (es) | Tieno (2,3-d) derivados de pirimidina y su uso para el tratamiento de la arritmia | |
MX345263B (es) | Formulación de pexiganan estable. | |
CL2008001948A1 (es) | Composicion de tetramatos 3-(2-alcoxi-4-cloro-6-alquil-fenil)sustituidos; uso de agentes tensoactivos seleccionados porque sirve para aumentar el efecto de un agente fitosanitario; procedimiento para preparar la composicion antes mencionada. | |
RU2009136584A (ru) | Растительное антгельминтное средство | |
BR112013027488A2 (pt) | Combinações de substâncias ativas e formulações cosméticas |